It is heartening that the Union Budget 2022 identifies Genomics and Pharmaceuticals as ‘sunrise’ sectors: Boehringer Ingelheim India
01 February 2022 | Views
Vani Manja, Country Managing Director, Boehringer Ingelheim India
“It is heartening that the Union Budget 2022 identifies Genomics and Pharmaceuticals as ‘sunrise’ sectors. This would enable well-rounded development beyond employment and access to enhanced industry efficiencies and competitiveness, which will go a long way in attracting increased investments in biopharmaceutical innovation. Our progress in research and development is inextricably linked to fostering a culture of innovation. Allowing for additional provisions towards establishing a stronger IPR ecosystem in the country is imperative to improve the Ease of Doing Index in India and further propel FDI in the pharmaceutical sector."
